
Boehringer Ingelheim's sNDA for OF EV (nintedanib) has been accepted by the FDA as a potential treatment for fibrosing interstitial lung disease (ILD) in children and adolescents aged 6 to 17. Childhood ILD often lacks approved therapies, causing a significant burden to patients and families. If approved, OFEV would become the first and only treatment for this age group, offering hope for those suffering from fibrosing ILD.
Like
Save
Share